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OBJECTIVE: In this retrospective cohort study, we
explored the UK General Practice Research database
(GPRD) to determine the hazard ratio of diabetes melli-
tus (DM) for patients prescribed antipsychotics compared
with the GPRD general patient population in the UK.
METHODS: An antipsychotic cohort comprised of
patients exposed to both conventional and atypical
antipsychotics (N = 46,111), individual antipsychotic
cohorts comprised of patients exposed to a single antipsy-
chotic, and a general patient population cohort (N =
266,272) derived from the GPRD database were studied.
A Cox proportional hazard regression model was used to
determine the hazard ratio (HR) of diabetes development
between these cohorts. The covariates included in the
model were age, gender, and the presence or absence of
obesity.
RESULTS: Compared to the GPRD general patient 
population cohort, patients exposed to antipsychotics
had a higher risk of developing diabetes (HR = 1.5; CI =
1.1–1.9). The risk of developing diabetes during exposure
to thioridazine and risperidone was signiﬁcantly higher
than that of the GPRD general patient population. Assess-
ment of other antipsychotics was limited by sample size
of the cohorts.
CONCLUSIONS: Patients exposed to antipsychotic
drugs have an increased risk of developing diabetes. 
It remains unclear to what extent the increased risk of
diabetes is related to treatment factors or factors related
to the underlying psychiatric conditions commonly
treated with antipsychotic drugs.
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OBJECTIVES: The Diabetes Prevention Program (DPP)
investigated the effects of intensive lifestyle changes (LsC)
or metformin (MET) on delaying the onset of type 2 
diabetes in overweight patients with impaired glucose 
tolerance (IGT). Patients randomized to either LsC or
MET 850mg twice daily reduced their risk of developing
type 2 diabetes by 58% and 31% respectively, compared
to controls. A simulation model was developed to explore
the long-term implications of delaying onset of type 2 
diabetes with LsC or MET.
METHODS: A Markov model combined data from DPP
with published data on mortality of IGT patients com-
pared to type 2 diabetes, in order to calculate the pos-
sible long-term effects of delaying the onset of diabetes
with LsC or MET on life expectancy (LE). The model
simulated 3 states. “IGT”, “type 2 diabetes”, and “dead”.
Annual transition probabilities for each treatment arm
were derived from the DPP, population studies, and
national mortality statistics. LE was calculated for each
treatment arm. Different assumptions were tested regard-
ing the post-trial effect of the delay of onset of diabetes.
Additional sensitivity analysis was performed to identify
other parameters with important impacts on LE.
RESULTS: Using the conservative assumption, LE from
baseline age of 51 years was 22.95, 23.12, and 23.03
years for the control, LsC, and MET groups respectively.
Using the optimistic assumption, LE further improved by
0.39 and 0.14 years for the LsC and MET groups respec-
tively. Other parameters with important impacts on LE
were the mortality rates in the states of “IGT” and “type
2 diabetes”.
CONCLUSIONS: Interventions that delay the onset of
type 2 diabetes in overweight IGT patients may lead to
important improvements in LE.
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OBJECTIVES: Unlike older agents, rosiglitazone lowers
blood glucose levels by directly acting on insulin resis-
tance, the primary metabolic defect of type 2 diabetes,
and has other positive metabolic effects on lipids and
blood pressure. Outcomes of patients on rosiglitazone
used as combination and monotherapy in routine 
Canadian clinical practice is reported.
METHODS: Five Canadian centers participated in retro-
spective data collection. Charts were reviewed for over
635 patients on rosiglitazone with the use of a software
program designed to track outcomes pre and post
Avandia treatment such as glycemic control, metabolic
parameters (including renal function, liver enzymes, 
and lipids) as well as weight, blood pressure and changes
in diabetic medications. Patient data were entered into 
the software and analyzed using standard statistical
methodology.
RESULTS: In the analysis of 337 patients on rosiglita-
zone, the average age was 71.6 years with 44% females.
Rosiglitazone was started as additional therapy to sulpho-
nylureas (38%) or metformin (42%) or both (33.5%).
There were 150 patients on rosiglitazone as monotherapy
(44%). The relative reduction in HbA1c was 15.3% at
